Pfizer’s PARP inhibitor Talzenna has become the first targeted treatment for HER2-negative locally advanced or metastatic breast cancer with BRCA1/2 mutations to be recomm
NICE has extended the number of patients eligible for treatment with Pfizer’s oral antiviral Paxlovid by around 1.4 million, as millions of doses of the COVID-19 therapy a
Leela Barham uses the very latest data – running up to November 2023 – to take stock of NICE’s Single Technology Appraisal (STA) recommendations on orphan drugs versus non-orphans.
NICE has set a new target for cholesterol levels in people who have had a heart attack or stroke to reduce the risk of them having another, encouraging the use of addition
Leela Barham digs into what’s publicly available on the success of NICE Advice just as the institute launched a refreshed offer to life sciences companies.